Your Asthma Drug Could Be a Cancer Game-Changer

Here’s a refreshing plot twist in the cancer-research world: a medication that’s been sitting in medicine cabinets for decades might hold a key to beating some of the toughest tumors out there.

Researchers at Northwestern University’s Feinberg School of Medicine have discovered that montelukast—better known by its brand name Singulair and commonly prescribed for asthma and allergies—could dramatically improve how well immunotherapy works against aggressive cancers. The breakthrough centers on a molecule called CysLTR1, which plays a starring role in inflammation and immune response. Tumors have learned to weaponize it, exploiting the molecule to trick the immune system into actually helping cancer grow instead of fighting it.

Here’s where it gets clever: the team found that tumors manipulate white blood cells called neutrophils, essentially conscripting them into the cancer’s defense force. But when researchers blocked CysLTR1—either genetically or with existing drugs like montelukast—they didn’t just slow tumor growth. They fundamentally rewired those harmful immune cells, reprogramming them to attack cancer instead. In mouse models testing triple-negative breast cancer, melanoma, ovarian cancer, colon cancer, and prostate cancer, blocking this pathway improved survival and restored immunotherapy’s effectiveness even in tumors that had already stopped responding to treatment.

The real game-changer? This drug is already FDA-approved. That means the path from lab bench to patient trials could move remarkably fast. Professor Bin Zhang and his team analyzed human immune cells and tumor samples alongside massive cancer datasets, and the pattern held: patients with higher CysLTR1 activity had worse survival rates and poorer responses to immunotherapy across multiple cancer types. The findings, published in Nature Cancer, suggest we’re not just looking at incremental progress—we’re looking at a way to rescue immunotherapy for patients who’ve run out of options.

What comes next is the careful work: confirming the mechanism works in actual patients, identifying who benefits most, and designing rigorous clinical trials to test montelukast as a companion to standard immunotherapy. For people battling aggressive cancers like triple-negative breast cancer, where new hope is desperately needed, this represents something genuinely different. A decades-old asthma drug might just be the immunotherapy catalyst oncologists have been searching for.